SCHEDULE 13G: Knight Therapeutics Discloses 17.03% Stake in Synergy CHC Corp.
Beneficial Ownership Report
Knight Therapeutics Inc. has reported a 17.03% beneficial ownership stake in Synergy CHC Corp., totaling 1,482,844 shares, as of December 31, 2024.
Summary
- Knight Therapeutics Inc., a Canadian entity, has filed a Schedule 13G indicating beneficial ownership of 1,482,844 shares of Synergy CHC Corp. common stock.
- This stake represents 17.03% of Synergy CHC Corp.'s total outstanding common stock.
- The percentage is calculated based on 8,703,818 shares of common stock issued and outstanding as of December 2, 2024, as disclosed by Synergy CHC Corp. in its Form 10-Q filed on December 6, 2024.
- Knight Therapeutics Inc. holds sole voting power and sole dispositive power over all 1,482,844 shares.
- The ownership comprises 1,096,693 shares held directly by Knight Therapeutics Inc. and an additional 386,151 shares held by its wholly-owned subsidiary, Knight Therapeutics International S.A.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the company's performance or outlook.
Positives
- Knight Therapeutics Inc. holds a significant beneficial ownership stake of 17.03% in Synergy CHC Corp., indicating a substantial investment by a Canadian pharmaceutical company.
Negatives
- No specific negative financial or operational details were disclosed in this beneficial ownership filing.
Risks
- The filing itself does not detail specific operational or financial risks for Synergy CHC Corp.; it is solely a beneficial ownership disclosure.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding future outlook.
Industry Context
Knight Therapeutics Inc. is a Canadian pharmaceutical company. Its significant investment in Synergy CHC Corp. suggests a strategic interest in the consumer health or pharmaceutical sector, aligning with potential industry consolidation or expansion strategies.
Comparison to Industry Standards
- This filing is a standard beneficial ownership disclosure (Schedule 13G) required when an entity acquires more than 5% of a company's stock, and it does not provide performance metrics for comparison to industry standards or specific comparable companies.
Related Party Transactions
- Knight Therapeutics Inc. holds 386,151 shares through its wholly-owned subsidiary, Knight Therapeutics International S.A. This is an internal ownership structure rather than a third-party related party transaction.
Stakeholder Impact
- Shareholders of Synergy CHC Corp. will be aware of a significant institutional investor holding a substantial stake in the company.
- Shareholders of Knight Therapeutics Inc. will be informed of a notable investment made by the company in Synergy CHC Corp.
Key Dates
| Date | Description |
|---|---|
| 2024-12-02 | Date as of which 8,703,818 shares of common stock were issued and outstanding for Synergy CHC Corp. |
| 2024-12-06 | Date Synergy CHC Corp. filed its quarterly report on Form 10-Q, disclosing the number of outstanding shares. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G. |
| 2025-03-19 | Date the Schedule 13G was signed by Knight Therapeutics Inc. |
Keywords
Synergy CHC Corp., Knight Therapeutics Inc., Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investment, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.